Moonwalk Biosciences received a Series B funding round from BioPharma Dive.
Public source
Publisher name
Public post
Thanks BioPharma Dive for speaking with our CEO Alex Aravanis MD PhD about our recent Series B funding. Sharing the article by Gwendolyn Wu: https://lnkd.in/eF_xk7_Z
Company
Moonwalk Biosciences
Pioneering novel therapeutics in adipose biology and tissue, driven by deep genetic and epigenetic insights
- Industry
- Biotechnology Research
- Location
- South San Francisco, US
- Company size
- 11–50 employees
About Moonwalk Biosciences
Moonwalk Biosciences is pioneering novel therapeutics in adipose biology and tissue, driven by deep genetic and epigenetic evidence and insights. It utilizes its discovery platform to identify novel targets involved in obesity and cardiometabolic disease, and is advancing an early stage pipeline of therapeutic candidates.
See moreLatest activity
Latest activity from Moonwalk Biosciences
11 signals
Products & Services
Moonwalk Biosciences advanced its adipose-targeted RNAi medicines for obesity and cardiometabolic diseases and its lead program MW101 toward the clinic.
Capital & Finance
Moonwalk Biosciences received $70 million Series B financing from the NYSE.
Research & Knowledge
Moonwalk Biosciences designed programs to selectively deliver siRNA therapeutics directly to adipose tissue to modulate novel non-incretin pathways underlying obesity.
Discover more
Similar signals
Similar public activity from other companies.
Capital & Finance
BiotechTV
BiotechTV reports that Bay Area based Moonwalk Biosciences announced a $70M series B funding round.
Capital & Finance
bioSeedin
bioSeedin closed an oversubscribed $70 million Series B financing for Moonwalk Biosciences to advance RNAi therapies for obesity and cardiometabolic diseases.
Capital & Finance
Alpha Wave Global
Alpha Wave Global co-led Moonwalk Biosciences' $70M Series B proceeds will support the advancement of MW101 into first-in-human clinical studies and accelerate development of a pipeline of adipose-selective RNAi medicines targeting novel biology.
Capital & Finance
Superluminal Medicines Inc.
Superluminal Medicines Inc. secured $60M Series B financing to advance its MC4R program into the clinic and build out its pipeline of GPCR-targeted medicines.
Capital & Finance
Flip Therapeutics